A:NYE-Agilent Technologies Inc. (USD)

EQUITY | Diagnostics & Research | New York Stock Exchange

Last Closing

USD 137.74

Change

0.00 (0.00)%

Market Cap

USD 14.27B

Volume

0.75M

Analyst Target

USD 102.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
TMO Thermo Fisher Scientific Inc

-2.33 (-0.39%)

USD 218.67B
DHR Danaher Corporation

-1.77 (-0.70%)

USD 186.23B
IQV IQVIA Holdings Inc

-5.04 (-2.15%)

USD 42.75B
LZAGF Lonza Group Ltd

-23.59 (-4.05%)

USD 41.97B
MTD Mettler-Toledo International I..

-48.61 (-3.22%)

USD 26.69B
WAT Waters Corporation

-1.83 (-0.52%)

USD 19.21B
LH Laboratory Corporation of Amer..

+2.70 (+1.30%)

USD 17.09B
DGX Quest Diagnostics Incorporated

+2.36 (+1.70%)

USD 15.38B
RVTY Revvity Inc.

+0.75 (+0.72%)

USD 12.54B
CRL Charles River Laboratories

+0.29 (+0.13%)

USD 11.85B

ETFs Containing A

TECX:CA TD Global Technology Lead.. 99.59 % 0.00 %

N/A

CAD 2.46M
TOCA:CA TD One-Click Aggressive E.. 16.24 % 0.00 %

N/A

CAD 0.08B
TOCM:CA TD One-Click Moderate ETF.. 14.25 % 0.00 %

N/A

CAD 0.05B
TOCC:CA TD One-Click Conservative.. 9.00 % 0.00 %

N/A

CAD 0.03B
DDOC:XETRA Global X Telemedicine & D.. 5.05 % 0.00 %

+0.09 (+1.08%)

USD 5.39M
DDOC:F Global X Telemedicine & D.. 5.05 % 0.00 %

-0.06 (1.08%)

USD 5.39M
EDOC:SW Global X Telemedicine & D.. 5.05 % 0.00 %

+0.06 (+1.08%)

USD 4.76M
EDOG:LSE Global X Telemedicine & D.. 5.04 % 0.00 %

+0.08 (+1.08%)

USD 0.68M
HHL-U:CA Harvest Healthcare Leader.. 5.03 % 0.00 %

-0.03 (1.08%)

N/A
HHL:CA Harvest Healthcare Leader.. 5.03 % 1.15 %

-0.02 (1.08%)

CAD 0.33B
HHL-B:CA Harvest Healthcare Leader.. 5.03 % 0.00 %

N/A

N/A
EDOC:LSE Global X Telemedicine & D.. 5.01 % 0.00 %

+0.15 (+1.08%)

USD 4.76M
GN0M:XETRA Global X Genomics & Biote.. 4.85 % 0.00 %

+0.09 (+1.08%)

USD 7.05M
GNOG:LSE Global X Genomics & Biote.. 4.66 % 0.00 %

+0.09 (+1.08%)

USD 6.47M
GNOM:SW Global X Genomics & Biote.. 4.47 % 0.00 %

+0.16 (+1.08%)

USD 6.40M
AHOY Tidal ETF Trust 4.25 % 0.00 %

-0.05 (1.08%)

USD 3.04M
XGES:LSE Xtrackers MSCI Genomic He.. 4.10 % 0.00 %

+0.12 (+1.08%)

USD 3.48M
FIW First Trust Water ETF 3.86 % 0.55 %

-0.65 (1.08%)

USD 1.72B
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.41 % 0.00 %

+0.01 (+1.08%)

N/A
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.37 % 0.00 %

N/A

USD 0.40B
ABIT:F AXA IM ACT Biodiversity E.. 2.37 % 0.00 %

+0.09 (+1.08%)

N/A
ABIE:F AXA IM ACT Biodiversity E.. 2.37 % 0.00 %

+0.13 (+1.08%)

N/A
2B78:XETRA iShares Healthcare Innova.. 1.74 % 0.00 %

+0.01 (+1.08%)

USD 1.14B
DRDR:LSE iShares Healthcare Innova.. 1.70 % 0.00 %

+0.13 (+1.08%)

USD 1.07B
HEAL:LSE iShares Healthcare Innova.. 1.68 % 0.00 %

+0.03 (+1.08%)

USD 1.07B
HEAL:SW iShares Healthcare Innova.. 1.68 % 0.00 %

+0.02 (+1.08%)

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

-0.05 (1.08%)

CAD 0.05B
GOAT 0.00 % 0.00 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.19 (+1.08%)

USD 0.09B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

+0.20 (+1.08%)

USD 0.05B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

+0.02 (+1.08%)

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.14 (+1.08%)

USD 3.48M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.93% 57% F 40% F
Dividend Return 0.17% 57% F 7% C-
Total Return -0.76% 57% F 35% F
Trailing 12 Months  
Capital Gain 1.71% 58% F 44% F
Dividend Return 0.68% 50% F 7% C-
Total Return 2.39% 58% F 34% F
Trailing 5 Years  
Capital Gain 75.46% 82% B 83% B
Dividend Return 5.14% 80% B- 17% F
Total Return 80.61% 82% B 82% B
Average Annual (5 Year Horizon)  
Capital Gain 17.01% 75% C 82% B
Dividend Return 17.74% 83% B 80% B-
Total Return 0.72% 83% B 17% F
Risk Return Profile  
Volatility (Standard Deviation) 29.96% 50% F 37% F
Risk Adjusted Return 59.20% 92% A 83% B
Market Capitalization 14.27B 77% C+ 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.90 58% 20%
Price/Book Ratio 6.66 38% 13%
Price / Cash Flow Ratio 22.78 46% 13%
Price/Free Cash Flow Ratio 24.88 23% 9%
Management Effectiveness  
Return on Equity 20.95% 77% 83%
Return on Invested Capital 15.04% 79% 78%
Return on Assets 7.85% 85% 87%
Debt to Equity Ratio 46.79% 54% 63%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.